Click here to sign in with or

by European Centre for Disease Prevention and Control (ECDC)

Given that there is no vaccine available against gonorrhea, diagnosing this sexually transmitted infection early, treating it effectively and notifying sexual partners are cornerstones of controlling disease spread. However, Neisseria gonorrhoeae has developed resistance to all classes of antimicrobials since the beginning of treatment with them in the 1930s.

As first-line treatment approach, current guidelines recommend either monotherapy with ceftriaxone or a combination of it with azithromycin but resistance or decreased susceptibility to both has been reported worldwide in recent years.

In their rapid communication published in Eurosurveillance, Pleininger et al describe the case of an extensively drug-resistant (XDR) Neisseria gonorrhoeae strain recently identified that shows high-level resistance to azithromycin and resistance to ceftriaxone, cefixime, cefotaxime, ciprofloxacin and tetracycline.

The strain was detected after a heterosexual male patient in Austria presented with symptoms in April 2022 following condomless sex with a female sex worker in Cambodia. The authors note a possible gonorrhea treatment failure with ceftriaxone and azithromycin as no post-treatment gonococcal isolates were available. Following the initial treatment course, the test of cure was negative, but a polymerase chain reaction test from the urethral swab culture sample was positive for Neisseria gonorrhoeae.

XDR gonorrhea challenges current treatment options and recommendations

According to Pleininger at al, the molecular investigation of the isolate establishes the detected strain in Austria as the second global gonococcal strain with ceftriaxone resistance combined with high-level azithromycin resistance and relatively close relationship with the "WHO Q" reference strain. The "WHO Q" strain has been associated with three cases of gonorrhea notified in the United Kingdom and Australia in 2018 with reported links to South East Asia.

Multidrug- and extensively drug-resistant Neisseria gonorrhoeae strains are a global public health concern given the limited remaining treatment options. Establishment of strains as described by Pleininger et al with sustained transmission might make many gonorrhea cases untreatable.

To address this, the authors conclude that "enhanced antimicrobial resistance surveillance (ideally including test of cure and whole-genome sequencing), nationally and internationally, particularly in Asia where many ceftriaxone-resistant strains appear to have emerged, is of highest importance. Ultimately, novel antimicrobials for effective treatment of gonorrhea and/or a sufficiently effective gonococcal vaccine will be crucial."  Explore further Failure of dual antimicrobial therapy for gonorrhea reported More information: Pleininger et al, Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022, Eurosurveillance (2022). DOI: 10.2807/1560-7917.ES.2022.27.24.2200455 Provided by European Centre for Disease Prevention and Control (ECDC) Citation: New strain of extensively drug-resistant Neisseria gonorrhoeae detected in Austria (2022, June 16) retrieved 24 June 2022 from https://medicalxpress.com/news/2022-06-strain-extensively-drug-resistant-neisseria-gonorrhoeae.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).

Please select the most appropriate category to facilitate processing of your request

Thank you for taking time to provide your feedback to the editors.

Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.

Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we'll never share your details to third parties.

Daily science news on research developments and the latest scientific innovations

The latest engineering, electronics and technology advances

The most comprehensive sci-tech news coverage on the web

This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.